autoimmune-Infectious-disease

I-Flash 1800 COVID-19

Key Facts

YHLO has introduced an effective automated CLIA testing for 2019-nCoV IgG/IgM.

CPC is the first company to launch the automated CLIA platform iFlash 1800 in INDIA, facilitating the fastest screening for COVID -19.

YHLO’s new 2019-nCoV IgG/IgM CLIA assays has the following advantages:

  • Fast reporting : 27 min.
  • Ease of sample collection : Serum or EDTA plasma.
  • Automated Assay : CLIA platform- 180 test/hr & 300 tests /hr.
  • Test Pack : 2 x 50 tests with builtin calibrators.
  • On board Stability : 28 days after opening.
  • Calibration stability : 28 days
First CLIA Assays

It is the first company to develop a CLIA platform for 2019-nCoV IgG and IgM antibodies which can satisfy the clinical needs to detect antibodies for new 2019-nCoV and offer differential diagnosis to doctors.

Fast Speed

iFlash 1800 offers comprehensive CLIA solutions up to 180 T/H for detecting 2019-nCoV . Fastest reporting in 27 min.

Stable Raw Materials

With a strong R&D team in protein engineering and immunoassay, YHLO achieves stable supply of the raw materials for these CLIA assays.

Strong Anti-Interference Ability

YHLO has made initial evaluation of these assays, and results showed that these assays have strong anti-interference ability to other respiratory pathogens (e.g. legionella Pneumophila, Mycoplasma Pneumonia, Chlamydia Pneumonia, Q Fever from Rickettsia, Adenovirus, RSV-Respiratory Syncytial Virus, Influenza A, Influenza B, Parainfluenza 1, 2, 3, etc.)

For more information please visit the website of YHLO with the below url:

Performance of SARS-CoV-2 IgM/IgG Kits in Thailand.
Contribution to Wuhan with SARS-CoV-2 IgG/IgM Assays.